This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
CRD COMMENTARY -Selection of comparators
The reason for the choice of comparator is clear. Closed needle biopsy has become a more widely used alternative to open biopsy.
Validity of estimate of measure of benefit
The estimate of measure of benefit used in the economic analysis is likely to be internally valid. The data have not been used selectively to compare the accuracy of the core needle and open biopsy.
Validity of estimate of costs
Adequate details of the methods of quantity/cost estimation were given and important cost items do not appear to have been omitted.
Other issues
The authors' conclusions are likely to be justified, although no sensitivity analysis was conducted to test for uncertainties in the data. The issue of generalisability to other settings was not addressed, although appropriate comparisons were made with other studies. The results were not presented selectively. A synthesis of the estimated benefits and costs could have been provided. A single benefit measure would have enabled a cost-effectiveness ratio to be calculated for each strategy and this would have enhanced the validity of the economic evaluation.
Source of funding
No funds were received in support of this study. 
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